Fulda Simone
Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstraße 3a, 60528 Frankfurt, Germany.
Sarcoma. 2012;2012:326210. doi: 10.1155/2012/326210. Epub 2012 Jan 12.
Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant expression of antiapoptotic proteins. Therefore, the identification of the molecular mechanisms that confer primary or acquired resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs. This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma.
横纹肌肉瘤对现有疗法的耐药性仍是儿科肿瘤学的关键问题之一。例如，大多数细胞毒性疗法（如化疗）治疗癌症的成功取决于介导程序性细胞死亡（凋亡）的完整信号通路，因此癌细胞凋亡程序中的缺陷可能导致耐药性。横纹肌肉瘤中凋亡逃避可能是由于凋亡关键介质的表达或功能缺陷，或抗凋亡蛋白的异常表达所致。因此，确定赋予横纹肌肉瘤原发性或获得性凋亡抗性的分子机制，是合理开发分子靶向药物的关键步骤。这种方法可能为横纹肌肉瘤的治疗开辟新的前景。
